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Abstract: The beneficial effects of black chokeberry fruits and juices in health 
promotion and prevention of chronic diseases shown in both epidemiological 
and dietary intervention studies are often connected with their antioxidant acti-
vity. The aim of this study was to investigate the total phenolics and anthocya-
nins content, chemical antioxidant activity (DPPH-assay), antioxidant protec-
tion in erythrocytes and anti-platelet activity in vitro of three different choke-
berry products: commercial and fresh pure chokeberry juice and a crude lyo-
philized water–ethanol extract of chokeberry fruits, as part of their pre-clinical 
evaluation. The obtained results indicated differences in chemical composition 
and antioxidant activity of the investigated products. Cellular effects, including 
both in vitro anti-platelet and antioxidant effects, were not directly correlated 
with the chemical antioxidant activity and the results obtained in vitro for anti-
platelet effects were only partially consistent with the results obtained in vivo, 
in a pilot intervention trial. In conclusion, chemical analyses and in vitro expe-
riments on foods and their bioactive substances are a valuable pre-screening 
tool for the evaluation of their biological activity. However, extrapolation of 
the obtained results to the in vivo settings is often limited and influenced by the 
bioavailability and metabolism of native dietary compounds or interactions 
with differrent molecules within the human body. 
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INTRODUCTION 
Black chokeberry (Aronia melanocarpa) belongs to the Rosaceae family. It 
is a native plant of North America and Canada, grown successfully in Europe 
since the beginning of the 20
th century. The fruits and juices of black chokeberry 
(A. melanocarpa) are excellent sources of both nutritive and non-nutritive dietary 
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compounds with numerous biological activities, including phenolics, vitamins 
and minerals. The phenolic compounds of chokeberries are procyanidins, antho-
cyanins, phenolic acids and tannins. Chokeberries are considered to be the best 
dietary sources of anthocyanins (25 % of total phenolics), one of the most power-
ful in vitro antioxidants. The fruits and juices of this plant have the highest anti-
oxidant activity compared to other types of berries from the Rosaceae family.1 A 
large number of dietary intervention studies showed the beneficial effects of the 
consumption of chokeberry juice and extracts on various risk factors for chronic 
diseases, including the parameters of oxidative stress,2 total cholesterol, LDL, 
oxy-LDL, triglycerides, glucose, HbA1c, systolic and diastolic blood pressure,3,4 
platelet5 and endothelial function.6 The effects of black chokeberry consumption 
are often connected with their antioxidant activity. However, the very low bio-
availability of anthocyanins observed after ingestion of anthocyanin-rich food 
questions the rationale for investigation of native compounds, instead of their 
metabolites, in in vitro models, in pre-screening for in vivo effects, including 
antioxidant activity. The aim of this study was to investigate the total contents of 
phenolics and anthocyanins, the chemical antioxidant activity (using the DPPH-
assay), cellular antioxidant activity and anti-platelet activity in vitro and ex vivo 
of three different chokeberry products: commercial and fresh pure chokeberry 
juice and a crude lyophilized water–ethanol extract of chokeberry fruits. 
EXPERIMENTAL 
Chemicals 
The following buffers and reagents were obtained from Sigma–Aldrich (Germany): 
phosphate-buffered saline (PBS), Folin–Ciocalteu’s phenol reagent, gallic acid, potassium 
chloride, sodium acetate, 2,4,6-tris(2-pyridyl)-s-triazine (TPTZ), ferrous sulphate heptahyd-
rate, 2,2-diphenyl-1-picrylhydrazyl (DPPH), Dulbecco’s modified Eagle’s medium (DMEM), 
hydrogen peroxide 30 % solution (H2O2), 3,4-dihydroxybenzoic acid (protocatechuic acid), 
calcein acetoxymethyl ester (calcein AM), foetal bovine serum (FBS), bovine serum albumin 
(BSA), adenosine diphosphate (ADP) and 2′,7′-dichlorofluorescein diacetate (DCF-DA). Mono-
clonal antibodies: fluorescein isothiocyanate (FITC)-conjugated PAC1, phycoerythrine (PE)-
conjugated CD62P, peridinin chlorophyll protein (PerCP)-conjugated CD61 and control immu-
noglobulin G-PE and immunoglobulin M-FITC were purchased from Becton Dickinson (USA). 
Subjects 
Whole blood was collected from subjects with metabolic syndrome for both in vitro 
experiments (n = 3) and ex vivo pilot study (n = 6; 3 males and 3 females). Metabolic synd-
rome was defined according to ATP III criteria.7 All blood samples were taken by venipunc-
ture according to the guidelines for blood sampling in platelet analysis. For the ex vivo pilot 
study participants were subjected to dietary intervention by acute intake of 200 mL of com-
mercial pure chokeberry juice and blood samples were collected before and 2 h after the 
consumption. Whole blood was used for the isolation of plasma and platelets. 
The study protocol was approved by the Ethical Committee of the Faculty of Pharmacy, 
University of Belgrade. The study was conducted in accordance with the revised Declaration 
of Helsinki. All participants provided written informed consent. 
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Samples 
Three different chokeberry products were used in the study: commercial pure chokeberry 
juice (CCJ) (Aronia Antioxi, Nutrika, Serbia), fresh pure chokeberry juice (FCJ) obtained in 
the laboratory by squeezing of fresh fruits (with a yield of 0.53 mL g-1 of fresh fruits) and 
crude lyophilized water–ethanol (40/60 % vol.) extract (WECE) of chokeberry fruits. All in-
vestigated chokeberry products were prepared from the fruits of Aronia melanocarpa var. ru-
bina, grown in western Serbia and harvested during October/November 2012. For the experi-
ments, the juices were diluted to the working concentrations in water or defined buffers. The 
crude water–ethanol extract was further extracted (50 mg mL-1) with water or methanol and 
soluble fractions (WCE and MCE, respectively) obtained by centrifugation were used in 
further experiments. For the cell-based assay, the methanol soluble fraction of investigated 
extract was evaporated to dryness in a rotary evaporator and the residue was reconstructed 
with water immediately before addition to the cells. The cell-based antioxidant activity and 
anti-platelet activity were also evaluated for protocatechuic acid, one of the major metabolites 
of cyanidin-3-glucoside.8  
Determination of the total phenolics 
Content of total phenolics in investigated samples was analysed using a modified Folin– 
–Ciocalteu method.9,10. Juices and extracts were diluted in distilled water to the working solu-
tions that gave absorbаnces within the standard calibration curve (0–600 µg mL-1 of gallic 
acid). The results are expressed as milligrams of gallic acid equivalents (GAE) per mL of 
juices or of the investigated extracts. Data are presented as mean ±SD for three replications. 
Determination of the total anthocyanins 
The total anthocyanin content (TAC) was quantified using the pH differential method 
described by Lee et al.11 Briefly, the investigated juices (CCJ and FCJ) and extract fractions 
(WCE and MCE) were dissolved in a potassium chloride buffer of pH 1.0 and sodium acetate 
buffer pH 4.5. The absorbance of both buffer solutions was measured at 520 and 700 nm. The 
results were expressed as milligrams of cyanidin-3-glucoside equivalents (CGE) per mL of 
juices or g of investigated extract. All experiments were performed in triplicate. 
Determination of the antioxidant activity 
Radical scavenging activity of the investigated samples was analysed using the DPPH 
assay.12 The data are presented as the concentrations of the samples that inhibited 50 % of the 
2,2-diphenyl-1-picrylhydrazyl (DPPH) radical (0.05 mM) after 30 min of incubation, based on 
the decrease in absorbance measured at 517 nm.  
The antioxidant activity of plasma obtained from whole blood before and 2 h after the 
dietary intervention with chokeberry juice was determined according to the method of Benzie 
and Strain,13 as the ability of the plasma to reduce ferric ions. The data are presented as the 
Fe(III) concentration (mM) in the sample after reaction with the ferric tripyridyltriazine (FeIII-
TPTZ) complex, according to the calibration curve (0–2000 µM FeSO4). All experiments 
were performed in triplicate. 
Determination of the antioxidant protection of erythrocytes 
The cellular antioxidant activity of the investigated samples was based on the antioxidant 
protection of erythrocytes exposed to reactive oxygen species (ROS). The cellular antioxidant 
protection assay was performed as previously described14 with modifications regarding the 
exposure of erythrocytes to a lower level of extracellular ROS (1mM H2O2). Packed erythro-
cytes were isolated from the whole blood of the donors by three subsequent washings with 
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PBS. The obtained erythrocytes, re-suspended in PBS, were treated with serial dilutions of the 
investigated samples (1 h, 37 °C). After incubation, the cells were washed twice with PBS to 
remove extracellular antioxidants, and incubated with the intracellular dye 2′,7′-dichlorofluo-
rescein diacetate (DCF-DA), washed again and treated with hydrogen peroxide (1 mM) for 30 
min. The intracellular ROS levels were analysed by flow cytometry (FACSCalibur, BD, USA) 
based on the fluorescence of dichlorofluorescein (DCF), fluorescent product of DCF-DA in 
the reaction with intracellular H2O2. The results are expressed as the mean fluorescence inten-
sity (MFI) of the total number of analysed erythrocytes (20000) and presented as mean ±SD of 
the data obtained in three subjects. All analyses were performed in duplicate. 
Determination of platelet activation – in vitro 
The platelet activation markers, P-selectin and GPIIb-IIIa, were measured by whole-
blood flow cytometry according to a previously published protocol15 with slight modifications 
for in vitro testing. In brief, after venipuncture, aliquots of dissolved (1:10 in Hepes-Tyrode 
Buffer, pH 7.4) anti-coagulated blood (3.2 % citrate) were incubated with serial (2×) dilutions 
of investigated samples (30 min, 37 °C) and subsequently incubated with CD61-PerCP (pan-
platelet marker), CD62P-PE (anti-P-selectin) and PAC-1-FITC (antiGPIIb-IIIa) monoclonal 
antibodies with suboptimal concentration of platelet agonists (0.5 mM ADP) for 20 min in the 
dark, at room temperature. After the incubation with antibodies, the samples were fixed with 
paraformaldehyde solution (0.5 %) for 15 min and analysed. Sample analysis was performed 
using a FACSCalibur flow cytometer with CellQuest software (Becton Dickinson, USA). The 
results are presented as antigen positive platelets (%) in the platelet pool (20000 events).  
Determination of platelet–endothelial cells adhesion – ex vivo  
The effect of chokeberry juice consumption on platelet–endothelial adhesion was inves-
tigated ex vivo in a platelet–endothelial cell adhesion assay. EA.hy926, a continuously repli-
cating cell line derived from primary human umbilical vein endothelial cells (HUVEC) was 
used as an endothelial cellular model. 
EA.hy926 cells were cultured as a monolayer in DMEM supplemented with penicillin 
(192 U mL-1), streptomycin (200 μg mL-1) and 10 % heat-deactivated FBS. The cells were 
grown at 37 °C in 5 % CO2 and humidified air atmosphere with twice-weekly subculture. 
Platelet-coated surfaces were prepared as described previously16 with modifications for 
ex vivo testing. Suspensions of platelets (0.1 mL containing 1×108 platelets in HEPES Ty-
rode’s buffer), isolated from the whole blood before and after intervention, were added to 
plastic flat-bottomed micro-titre wells. The plates were incubated for 24 h at 4 °C. The day 
after, non-adherent platelets were removed by washing with PBS containing 1 % BSA. The 
same solution was used for the blocking of “free adherent” sites on the plastic (1 h at 37 °C). 
EA.hy926 were detached and re-suspended in PBS enriched with Ca2+ and Mg2+. After 
staining with calcein-AM, 1×105 EA.hy926 cells were added to each platelet-coated well in 
the presence of thrombin (2 U mL-1) and incubated for 1 h at 37 °C. The plates were then 
washed twice and the adherent cells were quantified in black 96-well plates with a fluores-
cence plate reader (Florosken Ascent FL, Thermo) with an excitation wavelength of 485 nm 
and an emission wavelength of 520 nm. 
Statistical analysis 
All results are presented as mean ± standard deviation (SD). The data were analysed by 
the one sample t-test and p < 0.05 was considered statistically significant. The SPSS program, 
version 19 (SPSS Inc., Chicago, IL), was used for the analysis. 
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RESULTS AND DISCUSSION 
Total phenolics content 
The results of the total phenolics and anthocyanin content analysis, as well 
as the radical (DPPH) scavenging activity of the investigated samples are sum-
marized in Table I, showing values expressed per mL of juices and g of dry 
weight (DW) of the investigated juices, as well as per ml of the investigated ex-
tract fractions and g of investigated extract (WECE) used for the purpose of 
comparison. The total phenolics contents of CCJ and FCJ were similar (p = 0.79), 
showing that processes included in the production of the commercial juice (pec-
tinase treatment, filtration) did not influence the phenolics of the juice. The ob-
tained results were in accordance with the results of Mayer-Miebach et al.17 The 
contents of total phenolics in WCE and MCE, expressed as mg GAE per g of 
WECE dry weight (DW), were 4 and 2.5 times lower, respectively, than phenol-
lics content in the juices, calculated on DW. It could be concluded that the phe-
nolics present in 100 mL of juice could be provided with at least 35 g of the in-
vestigated extract, indicating that the extraction process should be further opti-
mized and/or prioritizing juice as the optimal source of chokeberry phenolics in 
future clinical studies. Results showing the significantly higher phenolic content 
in MCE compared to WCE (p < 0.001) also indicate that compounds with the 
phenolic structure present in WECE were extracted more efficiently with less 
polar solvents (methanol vs. water). 
TABLE I. Total phenolics content, total anthocyanins content and radical scavenging activity 
of the analysed samples; CCJ – commercial chokeberry juice; FCJ – fresh chokeberry juice; 
WCE – water soluble fraction of the water–ethanol (ϕwater = 0.40) extract of chokeberry fruits; 
MCE – methanol soluble fraction of the water–ethanol (ϕwater = 0.40) extract of chokeberry 
fruits; GAE – gallic acid equivalents; DW – dry weight; CGE – cyanidin-3-glucoside equiva-
lents 
Samples CCJ  FCJ  WCE  MCE 
Total phenolics, mg GAE mL-1 5.86±0.27  5.93±0.33  0.50±0.01 0.86±0.01 
Total phenolics, mg GAE g-1 DW  41.2±1.9  43.3±2.4 10.15±0.22  17.12±0.18 
Total anthocyanins, mg CGE mL-1 0.15±0.02 2.18±0.09  0.0210±0.004 0.21±0.01 
Total anthocyanins, mg CGE g-1 DW 1.07±0.14  15.91±0.65 0.42±0.02 4.12±0.18 
IC50
a / µL mL-1 0.44±0.03  0.52±0.03  7.41±0.46  4.12±0.38 
IC50 / mg DW mL-1 0.062±0.001 0.071±0.001 0.370±0.023 0.206±0.019 
aConcentration of samples that inhibited 50 % of DPPH radical, based on absorbance measurements at 517 nm 
Total anthocyanins content 
Total anthocyanins (TA) content in FCJ was significantly higher than in CCJ 
(p < 0.001), supporting previously published data on the influence of storage and 
processing on the content of anthocyanins. Howard et al.18 reported that both 
processing and storage of processed chokeberry products at ambient temperature 
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induced significant losses of anthocyanins. Anthocyanins in juices were more 
susceptible to the degradation processes compared to other products, due to the 
removal of skin and seeds. Degradation of anthocyanins is accompanied with an 
increase in the products of their polymerization, designed as polymeric pigments, 
but the precise mechanism is still unknown.  
The TA contents of WCE and MCE were 0.42±0.02 and 4.12±0.18 mg CGE 
g–1 DW, respectively. The observed significant difference between the obtained 
values (p < 0.001), indicate that anthocyanins were more efficiently extracted 
with methanol and the content in MCE was more than 10 times higher than in 
WCE and almost 4 times higher than in CCJ calculated on DW, showing that 100 
mL of CCJ is equivalent to approximately 3.7 g of extract. 
Antioxidant activity (DPPH assay) 
Antioxidant activity of juices and extracts was evaluated as the radical sca-
venging activity (RSA). After 30 min of incubation with 0.04 mM DPPH solu-
tion in methanol, 50% inhibition of absorbance measured at 517 nm (IC50 value) 
was obtained with 0.44±0.03 and 0.52±0.03 µL mL–1 of CCJ and FCJ, respecti-
vely, showing slight but significant difference between the obtained values (p = 
= 0.038) and surprisingly higher antioxidant activity of CCJ. Regarding investi-
gated extract MCE was more effective than WCE as DPPH radical scavenger, 
with the IC50 value of 0.206±0.019 and 0.370±0.023 mg of WECE used for ex-
traction (p = 0.007). RSA did not correlate with the anthocyanin content in inves-
tigated juices and extract fractions, indicating the influence of other bioactive 
substances present in the samples. In strawberries, DPPH radical scavenging acti-
vity was not significantly influenced by processing and storage and did not ref-
lect the decrease in anthocyanin content.19 However, RSA of extract fractions, 
based on quantities relevant for consumption, is negligible compared to the inves-
tigated juices and consequently could not be taken as optimal intervention sample. 
Antioxidant activity of plasma, measured using the ferric reducing antioxi-
dant power (FRAP) assay within in vivo pilot study in six subjects significantly 
increased after single intervention with commercial chokeberry juice (p = 0.001), 
with the obtained values of 1.51±0.26 mM Fe2+ compared to the baseline values 
of 1.29±0.23 mM Fe2+. The effect of acute intake of flavonoid-rich juice con-
sumption on FRAP value of plasma was observed previously, but the authors 
suggested that the effect may be due to changes in uric acid concentration.20 Data 
on acute intake of chokeberry juice on antioxidant capacity of plasma is lacking 
although Pilaczynska-Szczesniak et al. have shown that long term chokeberry 
juice consumption reduced parameters of lipid oxidation and increased the acti-
vities of antioxidative enzymes in erythrocytes.2 
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Antioxidant protection of erythrocytes 
Erythrocytes were used as a simple cellular model for the evaluation of the 
bioactive antioxidant effects of chokeberry against moderate oxidative stress in-
duced by hydrogen peroxide, influenced by the uptake through the biological 
membrane and overall bioavailability. Isolated red blood cells were pre-incubated 
with serial dilutions of investigated samples and exposed to H2O2 (1 mM). Intra-
cellular H2O2 levels were determined according to the measured DCF fluores-
cence using flow cytometry. As shown in a representative histogram presenting 
the decrease in DCF fluorescence in erythrocytes pre-treated with MCE (5 mg 
mL–1), compared to the non-treated cells, after the subsequent H2O2 exposure 
(Fig. 1), the mean DCF fluorescence (horizontal axis) of the analysed cells, cor-
responding with intracellular ROS levels, is shifted to the left to lower values 
compared to the fluorescence of non-pre-treated cells, indicating scavenging of 
H2O2. Figure 2 shows the decrease in intracellular ROS presented as the inhi-
bition of DCF fluorescence in the DCF-DA-stained cells pre-treated with different 
concentrations (1.25, 2.5 and 5 mg mL–1) of water soluble fraction (WCE) or 
methanol soluble fraction (MCE) of water–ethanol chokeberry fruit extract and 
subsequently exposed to H2O2 (1 mM), compared to the fluorescence in control 
cells (without pre-treatment). Based on the results obtained, both WCE and MCE 
showed antioxidant activity against H2O2-induced oxidative stress in erythro-
cytes, and the effect was more pronounced for MCE, with the inhibition levels (%) 
 
Fig. 1. Representative histogram showing DCF fluorescence decrease in erythrocytes pre-
treated with the methanol soluble fraction (MCE) of chokeberry extract and subsequently 
exposed to H2O2 (full area), compared to the fluorescence of non-pre-treated cells, exposed to 
H2O2 (purple borderline) and cells without H2O2 exposure (green borderline). 
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Fig. 2. Intracellular ROS decrease in erythrocytes pre-treated with different concentrations of 
the water soluble fraction (WCE) and methanol soluble fraction (MCE) of chokeberry extract 
and subsequently exposed to extracellular oxidative stress, compared to the control, non-pre-
treated cells (significantly different from control cells: *p<0.05 and **p<0.01). 
of measured fluorescence of 30.65±2.61 (p < 0.01), 36.67±3.98 (p < 0.01) and 
56.83±5.96 (p < 0.01), for the investigated concentrations of 1.25, 2.5 and 5 mg 
mL–1, respectively, compared to the values obtained for WCE of 16.89±4.78 (p <  
< 0.05), 8.69±7.45 (p = 0.18) and 43.42±12.08 (p < 0.05), for the same con-
centrations, respectively. The obtained results could be hypothetically explained 
with the higher amount of anthocyanins in the total content of phenolics of MCE. 
The main difference between the effects observed for MCE and WCE was the 
dose response, which was shown to be non-linear for WCE and linear for MCE, 
suggesting that the bioactive substances extracted with water or methanol could 
have antioxidant effects with different modes and activity. The inhibition level 
(%) was higher for MCE than for WCE at all the investigated concentrations, but 
was statistically significant only for 1.25 and 2.5 mg mL–1 (p < 0.05 and p < 0.01, 
respectively), showing that in higher concentrations, the cellular antioxidant ac-
tivity could be influenced by the uptake of potential antioxidants into the living 
cell. The effects of investigated juices were evaluated in the concentration range 
of 0.25–75 µL mL–1, with the maximum concentration hypothetically correlated 
with the concentration in plasma after the consumption of 200 mL of juice and 
the pre-assumption of complete availability of the bioactives present in the juices. 
Both juices showed antioxidant potential in concentrations corresponding to their 
IC50 values determined using DPPH assay, but the effect of FCJ was more pro-
nounced (p = 0.049) with an inhibition level (%) of 63.7±8.4 at the IC50 con-
centration (0.44 µL mL–1) compared to 47.3±5.7 obtained with CCJ at the IC50 
concentration of 0.52 µL mL–1. Interestingly, in the low concentration range 
(0.5–4 µL mL–1), the observed antioxidant activity was inversely correlated with 
concentration, while at higher concentrations, a direct correlation could be observed. 
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Slatnar et al. investigated the cellular antioxidant effects of different berry juices 
using Saccharomyces cerevisiae as an in vitro cellular model, DCF-DA staining 
but without ROS exposure. They showed that the results obtained in the yeast 
cells were markedly different from the data obtained by the DPPH assay and 
concluded that the major factors found to influence in vivo antioxidant activity 
were not only the cellular availability of the polyphenols present in juices but 
also the ratio of specific polyphenol present in the juices and consumed by the 
cell, with the favourable effects of the high anthocyanin content and low content 
of hydroxycinnamic acids. They also found that when the uptake of polyphenols 
by the yeast cells was low, the antioxidant activity increased. High hyd-
roxycinnamic acid uptake with low anthocyanin intake induced higher intracel-
lular oxidation.21 The cellular antioxidant activity of protocatechuic acid (PCA), 
a simple phenolic acid with in vitro antioxidant properties, was also investigated 
and it was found to be one of the major metabolites of cyanidin-glucosides.8,22 
The decrease in intracellular ROS, based on the inhibition of DCF fluorescence 
in DCF-DA stained cells pre-treated with different concentrations (10, 100 and 
1000 µM) of PCA and subsequently exposed to H2O2 (1 mM), compared to the 
fluorescence in control cells (without pre-treatment) is shown in Fig. 3. Anti-
oxidant protection of erythrocytes by PCA showed a statistically significant 
inverse dose response correlation (p = 0.0065), with the lowest dose (10 µM) 
that induced the highest reduction in intracellular ROS (52.09±7.29), suggesting 
that antioxidant activity of PCA is not mediated by its direct antioxidant action. 
The published data on the antioxidant properties of PCA within cellular systems 
and in animal models are controversial. Nakamura et al. showed dose and time 
dependant effects of PCA in animal models of skin tumours, with beneficial ef-
 
Fig. 3. Intracellular ROS decrease in erythrocytes pre-treated with different concentrations of 
protocatechuic acid (PCA) and subsequently exposed to extracellular oxidative stress, 
compared to the control, non-pre-treated, cells (significantly different from 
control cells: **p < 0.01). 
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fects of lower doses and pro-oxidant effects of higher doses and longer expo-
sure.23 At doses higher than 10 mM, PCA was also found to induce oxidative 
stress in both transformed and malignant cells from oral tissue, but in lower non-
toxic doses (2.5 mM), it sensitized cells to the pro-oxidant stimuli.24 Opposing 
results showing protective effects of PCA isolated from natural source against 
H2O2 induced oxidative stress both in vitro, in PC12 cells, as well as in vivo in 
animal models were reported by Shi et al.25 These discrepancies could be partly 
explained by the reported induction of cellular antioxidant enzymes by the lower 
concentrations of PCA.26 
Inhibition of platelet activation – in vitro 
The influence of the analysed samples on the expression of two activation 
markers, P-selectin and GPIIb-IIIa, on the platelet surface after ex vivo action of 
a suboptimal concentration of ADP was investigated. The effects were focused 
on the activities of WECE regarding its further use in clinical trials. As shown in 
Fig. 4, P-selectin expression in the whole blood platelets incubated with different 
concentrations (1.25, 2.5 and 5 mg mL–1) of the water soluble fraction (WCE) 
and the methanol soluble fraction (MCE) of the water–ethanol chokeberry fruit 
extract and subsequently treated with ADP (0.5 µM) was not significantly differ-
rent from the expression of this activation marker in activated non-pre-treated 
(control) cells. Inhibition levels (%) of P-selectin expression determined after 
incubation with 1.25, 2.5 and 5 mg mL–1 of WCE were –12.64±5.52, –4.84±13.09 
and 1.51±5.52, respectively, while with MCE, the obtained values were –2.86±5.99, 
1.37±3.72 and 7.50±5.73, respectively, and none of the observed changes were 
statistically significant. Linearity of the dose-response curves for the investigated 
concentrations and P-selectin expression were not observed either. Inhibition of 
 
Fig. 4. Inhibition of P-selectin expression in ADP-stimulated platelets pre-treated with 
different concentrations of the water soluble fraction (WCE) and methanol soluble 
fraction (MCE) of chokeberry extract compared to control, non-pre-treated cells. 
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the GPIIb-IIIa activation marker was influenced by the pre-treatment under the 
same experimental conditions with inhibition levels (%) of –2.96±1.83, 4.25±3.95 
and 18.83±8.36 for WCE, and –4.27±2.46, 4.28±1.49 and 21.18±8.79 for MCE, 
for concentrations of 1.25, 2.5 and 5 mg mL–1, respectively. Although the statis-
tical significance was compromised by the high inter-individual variations, dose-
response linearity could be observed (Fig. 5). CCJ and FCJ did not influence the 
expression of either of measured antigens in analysed concentration range (0.25– 
–75 µL mL–1). An effect of PCA in investigated concentration range (10–1000 
µM) was also not observed (data not shown). 
 
Fig. 5. Inhibition of GPIIb-IIIa expression in ADP-stimulated platelets pre-treated with 
different concentrations of the water soluble fraction (WCE) and methanol soluble fraction 
(MCE) of chokeberry extract compared to control, non-pre-treated cells. 
Expressions of the platelet surface antigens, P-selectin and GPIIb–IIIa, are 
sensitive indicators of platelet activation.15 P-selectin is a protein constitutively 
expressed in the α-granules of platelets and following platelet stimulation, it 
becomes expressed on the platelet surface. The active role of P-selectin in throm-
bosis, coagulation and its crucial role in the pathogenesis of atherosclerosis im-
plies mostly its role in leukocyte recruitment (notably monocytes) as an inflam-
mation process, mediated via its interaction with PSGL-1 (P-selectin glycopro-
tein ligand) constitutively expressed in almost all leucocytes.27 GPIIb-IIIa is an 
activation-dependent receptor for ﬁbrinogen and it mediates homotypic platelet 
aggregation with a crucial role in thrombosis.28 Based on the results of previous 
studies, dietary bioactive compounds, including polyphenols, can modulate plate-
let activation in response to agonist, both in vitro and ex vivo.29 Numerous stu-
dies reported beneficial effects of chokeberry products or extracts on platelet 
function in vitro, including reduction of nitrative and oxidative stress in plate-
lets30–32 and platelet aggregation,33,34 but anti-platelet effects regarding expres-
sion of GPIIb-IIIa in response to suboptimal ADP were not investigated previ-
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ously. Influence of chokeberry fruit extract on P-selectin expression after ADP 
action was previously investigated.35 Regarding the anti-platelet activity of PCA, 
previous studies showed that PCA selectively inhibited shear stress-induced pla-
telet activation and aggregation but did not inhibit platelet aggregation induced 
by ADP and other endogenous agonists (collagen, thrombin). The proposed me-
chanism of the observed effects of PCA is the blockage of the von Willebrand 
factor binding to the activated glycoprotein Ib.36 
Inhibition of platelet–endothelial cells adhesion – ex vivo pilot study 
The ex vivo effects of CCJ consumption were assessed by employment of the 
platelet–endothelial cells adhesion  assay, according to a previously described 
procedure. Adhesion of platelets, isolated 2 h after the consumption of CCJ, to 
endothelial cells (EA.hy926) in culture in the presence of thrombin was inhibited 
in all subjects compared to the adhesion of the platelets isolated before the con-
sumption. The mean value of inhibition (%) obtained in six subjects was 
37.83±22.64, showing significant inhibition of platelet adhesion after chokeberry 
juice consumption (p = 0.009) with a marked inter-individual variation of the 
obtained values. The results obtained in this pilot study indicate a rationale for 
future investigation of the observed effects in a larger population and within a 
controlled study.  
As platelet–endothelial adhesion is considered to be a GPIIb-IIIa dependant 
process,37 the results obtained in vivo are consistent with the results obtained for 
GPIIb-IIIa inhibition in vitro. It is noteworthy that the results of the present pilot 
study investigating the effects of CCJ consumption on both P-selectin and GPIIb-
IIIa expression after ex vivo suboptimal ADP action, evaluated by flow cyto-
metry, were also observed (data not shown). The in vitro effects of chokeberry 
extract on platelet–endothelial cells adhesion was previously investigated by Lu-
zak et al., who reported that incubation with a low concentration (5 µg mL–1) of 
chokeberry extract increased the efficacy of human umbilical endothelial cells in 
culture to inhibit ADP activated platelet adhesion in vitro.35 In the performed 
study, the effects of chokeberry consumption targeted on the function of platelets 
were investigated. The assay itself has numerous advantages in the screening of 
different agents for in vitro anti-platelet  effects targeted at the inhibition of 
GPIIb-IIIa or endothelial cell-mediated inhibition of platelet aggregation or effect 
of the consumption food and food bioactives on ex vivo agonist-induced platelet 
activation and the consequential platelet adherence to endothelial cells in culture.  
The only reliable option to confirm the beneficial effects of anthocyanin-rich 
food in health promotion and the prevention of chronic diseases and to prove the 
hypothesis that the effects mostly rely on anthocyanins is to conduct a human 
intervention study designed as a randomized placebo-controlled trial. Numerous 
constrains on intervention trials with anthocyanins within food matrix include the 
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design of the placebo, the rapid degradation of the bioactive substances, the rele-
vancy of their antioxidant activity in pre-screening for relevant effects of cardio-
vascular diseases (CVD) and surrogate outcomes.  
Biological relevance of direct antioxidant effects of polyphenols in the pre-
vention of chronic diseases, including cardiovascular disease, has recently been 
re-evaluated. More often experts in the field accept the opinion that the direct 
antioxidant effect could not explain the numerous health effects observed in both 
intervention and epidemiological studies.38 This opinion is based on their poor 
bioavailability, low concentrations in blood compared with other antioxidants 
and the decline in their antioxidant activity following ingestion. Based on the 
results obtained in this study, the in vitro antioxidant potential is not reliable for 
the prediction of numerous effects relevant in CVD prevention.  
The degradation of anthocyanins within berry products (especially juices) 
could be an issue in long term trials and additional strategies for mitigating 
anthocyanins losses during the intervention period are required. The extract of 
chokeberries evaluated in this study did not provide satisfactory results compared 
to the juice and cellular in vitro effects were obtained in high non-relevant doses 
regarding formulation in dosage forms or juice supplementation, suggesting that 
further optimization in the extraction process is needed. Two cell-based assays, 
investigating the antioxidant potential and anti-platelet effects were also not 
correlated for the evaluated fractions of extracts, showing that antioxidant acti-
vity is not always a prerequisite for other cellular effects as previously sug-
gested.38 The in vitro anti-platelet effects, although evaluated at high concentra-
tions of extract, are supported by the pilot ex vivo trial, but the final conclusions 
could be made only in an intervention trial. Subjected to intense metabolic trans-
formation, the bioactives could also provide metabolites with opposing effects, 
compared to the native forms. The effects of long-term consumption of choke-
berry extract on platelet aggregation induced by ADP ex vivo were recently re-
ported in patients with metabolic syndrome,5 but the effects on specific activa-
tion markers and both homotypic and heterotypic platelet aggregation, with opti-
mal and suboptimal agonist action should be further investigated.  
In conclusion, a multifaceted approach in preclinical investigation is the opti-
mal strategy in the screening for potential candidates for health promotion and 
prevention of chronic diseases, but it still could not guarantee the effects in vivo. 
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ИЗВОД 
ИСПИТИВАЊЕ БИОЛОШКЕ АКТИВНОСТИ АНТИОКСИДАНАСА АРОНИЈЕ 
(Aronia melanocarpa) У ДИЗАЈНИРАЊУ ИНТЕРВЕНТНИХ СТУДИЈА 
АЛЕКСАНДРА КОНИЋ РИСТИЋ
1, ТАТЈАНА СРДИЋ РАЈИЋ
2, НЕВЕНА КАРДУМ
1 И МАРИЈА ГЛИБЕТИЋ
1 
1Центар изузетне вредности у области истраживања исхране и метаболизма, Институт за 
медицинска истраживања, Универзитет у Београду, Др Суботића 4, 11000 Београд и 2Институт за 
онкологију и радиологију, Универзитет у Београду, Пастерова 13, 11000 Београд 
Повољни ефекти плодова и сокова ароније у промоцији здравља и превенцији бо-
лести показани су у многим епидемиолошким и интервентним студијама и веома често 
се повезују са антиоксидативним деловањем њихових састојака. Циљ ове студије је био 
да се испита антиоксидативно деловање на еритроцитe и анти-тромбоцитно деловање 
три различита производа добијена од плода ароније: комерцијалног сока, свеже цеђеног 
сока и лиофилизованог водено–етанолног екстракта плода ароније, у in vitro експери-
менталним  условима.  Добијени  резултати  поређени  су  у  односу  на  садржај  укупних 
полифенола и антоцијана, као и на антиоксидативну активност одређену DPPH тестом. 
Резултати  су  указали  на  значајне  разлике  у  хемијском  саставу  и  антиоксидативној 
активности испитиваних производа, али директна веза са ефектима на ћелијама, укљу-
чујући  и  антиоксидативно  деловање  на  еритроцитe  и  анти-тромбоцитно  деловање  in 
vitro, није показана. Резултати добијени ex vivo у оквиру пилот студије, са једним од 
испитиваних узорака, једним делом су потврдили резултате добијене in vitro. На основу 
резултата  добијених  испитивањем  антиоксиданаса  ароније  показано  је  да  хемијска 
анализа и in vitro експерименти на ћелијским моделима имају велики значај у процени 
њихове биолошке вредности. Екстраполација добијених резултата у ситуацију in vitro је, 
међутим, често отежана и под утицајем биорасположивости и метаболизма дијетарних 
биоактивних супстанци. 
(Примљено 13. децембра 2012, ревидирано 7. фебруара 2013) 
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